Predictmedix Business Summary

QScreen AI Inc. (formerly Predictmedix AI Inc.) operates a multi-vertical healthcare technology model centered on its proprietary Core AI Engine, which utilizes multispectral imaging and quantum-inspired algorithms for contactless health screening. The company generates recurring revenue through a Screening-as-a-Service (SaaS) model, charging monthly subscription fees for its SmartHealth AI Stations and its clinical-trial optimization platform. Its primary business segments include Workplace Health and Safety, focusing on rapid impairment (alcohol/cannabis) and infectious disease detection; Clinical-Trial AI, providing simulation and patient-matching tools; and Consumer Digital Health, which offers mobile-based vital sign monitoring. QScreen AI competes with specialized firms such as BioIntelliSense, Buzzkill Labs, and Qure.ai, positioning itself as a niche leader by providing high-throughput, non-invasive screening that eliminates the need for biological samples or physical contact. The leadership team is anchored by Co-founder and COO Dr. Rahul Kushwah, a Banting Fellow and former scientist at the National Research Council of Canada with deep expertise in immunology and medical genetics. The executive suite is led by CEO and President Sheldon Kales, a serial entrepreneur with over 30 years of experience in managing R&D operations and taking technology firms public. Financial oversight is managed by CFO Rakesh Malhotra, a dual-certified CPA with extensive experience in international reporting. The company’s Board of Directors includes independent members David Goodman and Jun Yu, who provide strategic governance in technology scaling and capital markets. Recent strategic engagements with Global Frontier Advisors L.P. and participation in federal trade missions underscore the company’s focus on institutional and government-level commercialization across North America.